RxDoctor Payments Data

Eric Marks, MD

Medical Oncology · Boston, MANPI 1952729717

Payments from drug & device makers

$387,778in general payments, 2019–2025

Across 24 payments — averaging $16,157 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Deciphera Pharmaceuticals Inc.$258K
  • Merck$98K
  • AstraZeneca$31K

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Deciphera Pharmaceuticals Inc.16$258,360
Merck7$97,956
AstraZeneca1$31,462

How this compares

$387,778 in reported general payments places this provider in the 65th percentile of 308 medical oncology providers in Massachusetts.

See all medical oncology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$23,062
Medicare patients
53
Services billed
199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prochlorperazine Maleate32$475
Dexamethasone33$192
LoperamideLoperamide Hcl15$120

Paid to pharmacies, not to this prescriber.

Other medical oncology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →